XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Earnings Per Share and Stockholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2018
Earnings Per Share [Abstract] |
Earnings Per Share and Stockholders' Equity | Earnings Per Share and Stockholders' Equity Earnings Per Share The following table sets forth the computation of earnings per common share and earnings per common share - assuming dilution:
| Year Ended December 31,
| 2018 |  | 2017 |  | 2016
| (Dollars in thousands, except per share data)
Numerator: |  |  |  |  |
Net income - numerator for earnings per common share | $ | 458,016 |  |  | $ | 174,645 |  |  | $ | 83,243 |
Denominator: |  |  |  |  |
Weighted average common shares outstanding | 90,347,915 |  |  | 88,982,442 |  |  | 84,793,151 |
Effect of dilutive securities: |  |  |  |  |
Warrants | — |  |  | — |  |  | 15,136 |
Stock options and deferred compensation agreements | 709,433 |  |  | 945,612 |  |  | 456,236 |
Restricted stock and restricted stock units | 365,237 |  |  | 382,954 |  |  | 340,646 |
Denominator for earnings per common share - assuming dilution | 91,422,585 |  |  | 90,311,008 |  |  | 85,605,169 |
Earnings per common share | $ | 5.07 |  |  | $ | 1.96 |  |  | $ | 0.98 |
Earnings per common share - assuming dilution | $ | 5.01 |  |  | $ | 1.93 |  |  | $ | 0.97 |
Options to purchase shares of our common stock that were outstanding during the respective periods indicated but were not included in the computation of diluted earnings per share because the options' exercise price was greater than the average market price of the common shares are as follows:
Period |  | Number of Shares |  | Range of Exercise Prices
|  |  |  | Minimum |  | Maximum
Year ended December 31, 2018 |  | — |  | $— |  | $—
Year ended December 31, 2017 |  | — |  | $— |  | $—
Year ended December 31, 2016 |  | 1,054,091 |  | $24.79 |  | $24.79
Stockholders' Equity In August 2015, we completed an underwritten public offering of 8,600,000 shares of our common stock at a public offering price of $25.25 per share, of which 4,300,000 shares were subject to a forward sale agreement. The underwriters exercised in full their option to purchase 1,290,000 additional shares of common stock, which were subject to a separate forward sale agreement. We settled the forward sale agreements on August 1, 2016 and issued 5,590,000 shares of our common stock and received $134.7 million in net proceeds. We contributed the net proceeds from the settlement to the capital and surplus of American Equity Life. The forward sale agreements had no initial fair value since they were entered into at the then market price of the common stock. The forward sale agreements were equity instruments and qualified for an exception from derivative and fair value accounting.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration